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Abstract
Background: Endophenotypes are quantitative, laboratory-based measures representing intermediate links in the pathways
between genetic variation and the clinical expression of a disorder. Ideal endophenotypes exhibit deficits in patients, are
stable over time and across shifts in psychopathology, and are suitable for repeat testing. Unfortunately, many leading
candidate endophenotypes in schizophrenia have not been fully characterized simultaneously in large cohorts of patients
and controls across these properties. The objectives of this study were to characterize the extent to which widely-used
neurophysiological and neurocognitive endophenotypes are: 1) associated with schizophrenia, 2) stable over time,
independent of state-related changes, and 3) free of potential practice/maturation or differential attrition effects in
schizophrenia patients (SZ) and nonpsychiatric comparison subjects (NCS). Stability of clinical and functional measures was
also assessed.
Methods: Participants (SZ n= 341; NCS n= 205) completed a battery of neurophysiological (MMN, P3a, P50 and N100
indices, PPI, startle habituation, antisaccade), neurocognitive (WRAT-3 Reading, LNS-forward, LNS-reorder, WCST-64, CVLT-II).
In addition, patients were rated on clinical symptom severity as well as functional capacity and status measures (GAF, UPSA,
SOF). 223 subjects (SZ n= 163; NCS n= 58) returned for retesting after 1 year.
Results: Most neurophysiological and neurocognitive measures exhibited medium-to-large deficits in schizophrenia,
moderate-to-substantial stability across the retest interval, and were independent of fluctuations in clinical status. Clinical
symptoms and functional measures also exhibited substantial stability. A Longitudinal Endophenotype Ranking System
(LERS) was created to rank neurophysiological and neurocognitive biomarkers according to their effect sizes across
endophenotype criteria.
Conclusions: The majority of neurophysiological and neurocognitive measures exhibited deficits in patients, stability over
a 1-year interval and did not demonstrate practice or time effects supporting their use as endophenotypes in neural
substrate and genomic studies. These measures hold promise for informing the ‘‘gene-to-phene gap’’ in schizophrenia
research.
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Introduction
One prominent strategy for deconstructing complex, heritable
neuropsychiatric disorders such as schizophrenia is to examine
discrete, genetically determined ‘‘endophenotypes’’ that are part of
the illness and detected in the laboratory rather than by ‘‘the
naked eye’’ of the clinical interview [1]. Endophenotypes may be
useful for deconstructing the complexity of clinical, neural
substrate, and genetic underpinnings of the disorder [2,3]. Several
criteria for viable endophenotypes have been proposed [1,4–6].
While there is some variability in the criteria, in general,
endophenotypes are a subset of biomarkers that: 1) are associated
with the illness, i.e., exhibit deficits in patients; 2) are stable over
time; 3) are relatively independent of fluctuations in clinical
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symptoms; 4) show similar, though often lesser deficits in clinically
unaffected family members; and 5) are heritable. This study
addresses criteria 1–3 above. Thus, endophenotypes are quanti-
tative, laboratory-based measures that represent intermediate links
in the pathways between genetic variation and the clinical
expression of the disorder that can uniquely inform the ‘‘gene-
to-phene’’ knowledge gap.
Some widely used candidate neurophysiological endopheno-
types in schizophrenia include prepulse inhibition of the acoustic
startle reflex (PPI), P50 and N100 event-related potential
amplitudes and gating, oculomotor antisaccade, mismatch nega-
tivity (MMN), and the P3a event-related potentials [2,6,7].
Commonly used neurocognitive endophenotypes include mea-
sures of attention, working memory, verbal recall, perseverative
thinking and rule learning in response to verbal feedback [8,9].
Increasingly, these and other neurophysiological and neurocog-
nitive measures are used as biomarkers in clinical trials for ‘‘proof
of concept’’ studies designed to determine whether a drug has
a detectable ‘‘neurobiological signal’’ or as outcome measures to
determine if a drug improves cognition [10–15]. In this context,
the Measurement and Treatment Research to Improve Cognition
in Schizophrenia (MATRICS) expert panel has established criteria
that are considered ‘‘essential’’ for measure selection in clinical
trial studies designed to improve cognition in schizophrenia [16].
These criteria are: 1) good test-retest reliability; 2) utility as
a repeated measure (i.e., no practice effects); 3) a relationship to
functional outcome; 4) a potential response to pharmacologic
agents; and 5) practicality/tolerability. Thus, although endophe-
notypes and biomarkers share some common desirable character-
istics [17,18], further validation is required before treatment and
clinical trial applications using these measures can be fully
implemented.
The long-term stability of many neurocognitive measures in
schizophrenia outpatients appears to be well-established (e.g.,
[19,20]). Relatively few studies, however, have examined the test-
retest reliability of commonly used neurophysiological biomarkers
in schizophrenia patients [17,21,22]. Longitudinal studies of at
least 6 months to one year are essential for disentangling state and
trait influences and detecting enduring relationships among
endophenotypes and clinical outcome measures (e.g., [23–25]).
Thus, the aims of the present study were to characterize the extent
to which a battery of 15 frequently used but not as yet fully
validated candidate neurophysiological and neurocognitive mea-
sures fulfill many of the established criteria of endophenotypes and
biomarkers of drug response including the extent to which
measures are deficient in a large cohort of schizophrenia patients,
stable over 1 year, and independent of symptom fluctuations in
schizophrenia outpatients relative to nonpsychiatric comparison
subjects (NCS). Secondary analyses also included assessments of
potential practice effects (i.e., subjects’ performance improves due
to increased familiarity with the test) and differential attrition (i.e.,
differences in baseline characteristics in patients who returned vs.
failed to return for repeat testing).
We hypothesized that the heritable neurophysiological and
neurocognitive measures (e.g., [7,22]) would show deficits in
schizophrenia patients, exhibit at least moderate (ICCs.0.60) test-
retest stability with little evidence of practice/maturation effects or
relationships to fluctuations in clinical symptoms as is commonly
assumed in the genetics of schizophrenia literature. We also
hypothesized that the schizophrenia patients that failed to return
Figure 1. Schizophrenia patient study enrollment and reasons for not being retested.
doi:10.1371/journal.pone.0039434.g001
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for repeat testing would differ in their baseline (T1) characteristics
with ‘‘non-returners’’ being generally more symptomatic, showing
worse neurocognitive performance and having poorer functional
status vs. those patients who returned for re-testing after 1 year
(T2).
Methods
Subjects
This study was approved by the University of California, San
Diego Human Research Protections Program Institutional Review
Board. All participants were assessed and judged to be capable of
providing informed consent and, after subjects were given
a detailed description of study procedures, written consent was
obtained per UCSD IRB-approved protocols (IRB# 071128 and
071831) prior to each testing session. Participants included 546
subjects: 341 schizophrenia patients and 205 nonpsychiatric
comparison subjects (NCS). Schizophrenia patients were recruited
from community residential facilities and via physician referral.
Normal comparison subjects were recruited through newspaper
and internet advertisements and fliers posted at the UCSD
Medical Center. All subjects received a urine toxicology screen to
rule out recent drug use. In addition, patients and NCS were
assessed using the Structured Clinical Interview for DSM-IV [26].
This interview was used to ensure that NCS did not meet criteria
for an Axis I or Axis II Cluster A diagnosis Family history of
psychiatric disorders was also assessed to ensure that NCS did not
have a first-degree relative with a psychotic disorder [27]. In
addition, patients did not have a current Axis I diagnosis other
than schizophrenia. All subjects were carefully screened to ensure
they had never experienced a neurologic insult, such as significant
head trauma and/or loss of consciousness as per our established
methods [24,28,29]. Audiometric testing was used to ensure that
all participants could detect 40-dB tones at 1000 Hz for their data
to be used in PPI, MMN, P3a, P50/N100 measures. There were
neither statistically significant differences in hearing thresholds
between the schizophrenia patient and NCS groups nor significant
correlations between hearing thresholds and dependent measures.
Data from subsets of these 546 participants who completed
baseline testing were reported previously [29–32], including
preliminary genetic association findings of a subset of 219 subjects
of European ancestry and 76 subjects of African ancestry recently
published in this journal [3].
Schizophrenia patients (n = 163) and NCS (n= 58) were retested
using identical procedures and the same fixed order of tests after
approximately 1 year (mean number of days (SD) SZ: 365.34
(26.44); NCS: 363.95 (18.13) days; t =20.37, p = 0.71) in order to
characterize the stability of the measures as well as relationships to
changes in clinical symptoms. As shown in Figure 1, of the 178
patients who were not retested, reasons for not returning were as
follows: 62% were unable to be re-contacted, 26% were not
invited to return by the study staff and investigators (e.g., unable to
Figure 2. Deficits in schizophrenia patients across measures. Effect sizes (Cohen’s d) calculated from group main effects (Table 2) collapsed
across time.
doi:10.1371/journal.pone.0039434.g002
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tolerate testing procedures, removed electrodes and/or showed
excessive artifact during testing), 9% declined to return, and 3
subjects were excluded on retest (positive toxicology screen, failed
hearing test). Medications were not experimentally controlled in
this study. Among the retested patients, 6 were not treated with an
antipsychotic (AP), 14 were prescribed 1st generation AP, 113
patients 2nd generation AP, and 30 received a combination of 1st
and 2nd Generation AP when they came in for their initial (T1) test
session. Over the retest interval, 44 patients underwent a change in
the AP, with the majority (n = 22) switching from one to another
primary 2nd generation AP.
Clinical and Functional Assessment Measures
In the schizophrenia patients, clinical symptoms were assessed
with the Scale for the Assessment of Negative Symptoms (SANS;
[33]) and the Scale for the Assessment of Positive Symptoms
(SAPS; [34]). Functional status was assessed using a modified
version of the Global Assessment of Functioning Scale (GAF; [35])
and the Scale of Functioning (SOF; [36]). Functional capacity was
assessed using the UCSD Performance Based Skills Assessment
(UPSA; [37]). To evaluate the relative stability of the abbreviated
version of the UPSA, UPSA-Brief scores were also derived from
the full scores in accordance with established methods [38].
Neurophysiological and Neurocognitive Measures
The following neurophysiological and neurocognitive mea-
sures were assessed using our established parameters in a fixed
battery: PPI [29,30], startle habituation [39], P50 and N100
amplitudes and suppression measures [30,40], MMN and P3a
amplitudes [24,31,32,41,42], oculomotor antisaccade [43], sim-
ple auditory attention (Letter-Number Span Forward; LNS-
Forward; [44], working memory (Letter-Number Span Re-
order; LNS-Reorder; [44,45]), immediate verbal recall (Califor-
nia Verbal Learning Test-2, Standard Form; CVLT-II; [46]),
perseverative thinking and rule learning in response to verbal
feedback (Wisconsin Card Sorting Test-64; WCST-64 [32]).
The test order was as follows: PPI and startle habituation,
oculomotor antisaccade, LNS-Forward, LNS-Reorder, CVLT-II,
WCST-64 followed by a lunch break. After the break,
particpants underwent EEG testing for P50 and N100 measures
followed by MMN and P3a. For EEG testing, a 40 channel
NeuroScan NuAmps system was used with sintered Ag/AgCl
electrodes arranged in an electrode cap (EasyCap) with
a forehead ground and nose reference. For N100, MMN, and
P3a measures, amplitudes were measured relative to a 100 msec
prestimulus baseline.
Mismatch negativity and P3a. Stimulation, recording, and
analysis techniques for calculating MMN and P3a amplitudes
followed our previously established methods [24,28,31,32,41,42].
Figure 3. Changes in measures over 1 year retest interval in schizophrenia patients. Effect sizes (Cohen’s d) of changes in neurocognitive
and neurophysiological measures across the retest interval.
doi:10.1371/journal.pone.0039434.g003
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Subjects were presented with binaural stimulation (1 kHz com-
puter-generated square wave stimuli, 85 dB[A] SPL, 1 msec rise/
fall) with a fixed stimulus onset-to-onset asynchrony of 500 msec.
Standard (P = 0.90; 50 msec duration) and deviant (P = 0.10;
100 msec duration) stimuli were presented in a pseudorandom
order while participants watched a silent cartoon video. Signals
were digitized at a rate of 1 kHz with system acquisition filter
settings at 0.5–100 Hz. Testing was terminated after a minimum
of 225 artifact-free responses to deviant stimuli was collected using
the same automated procedures as described above. MMN and
P3a waveforms were generated by subtracting ERPs in response to
standard tones from the ERPs generated in response to the deviant
tones. The MMN and P3a amplitudes were calculated from
electrode Fz as the mean voltage from 135–205 and 250–
300 msec ranges, respectively, consistent with established methods
[24,28,32,42].
Prepulse inhibition. Subjects were seated in a reclining
chair in an upright position. The session began with a 5-min
acclimation period with 70 dB[A] white noise that continued as
the background throughout the session. All startle pulse stimuli
Table 1. Assessment of differential attrition.
Schizophrenia Patients (N=341) Not-Retested (n=178) Retested (n=163) d
Mean SD Mean SD
Demographic Characteristics
Gender (% male) 71.91 – 73.00 – –
Age 43.38 10.06 45.49 9.37 20.22
Years of Education Completed 11.84 2.27 11.98 1.99 20.07
Age of Illness Onset 21.59 7.36 21.88 7.19 20.04
Duration of Illness 21.91 10.61 23.61 10.30 20.16
Number of Hospitalizations 9.56 14.48 8.10 11.90 0.11
Hearing Threshold 1000 Hz 18.67 8.30 18.95 7.86 20.03
Clinical and Functional Characteristics
SAPS Total Score 9.39 3.94 8.32 4.38 0.26
SANS Total Score 13.89 3.95 13.60 4.55 0.07
Global Assessment of Functioning Scale 40.70 6.50 41.75 8.11 20.14
Scale of Functioning Total Score 46.50 6.09 47.57 6.27 20.17
UCSD Performance Based Skills Assessment (Total) 77.58 15.04 79.09 13.56 20.11
Neurocognitive Performances
Single-word reading (WRAT-3 Reading) 43.01 7.95 44.23 6.88 20.16
Simple Attention (LNS-Forward) 11.34 3.05 11.90 3.04 20.18
Working Memory (LNS-Reorder) 7.27 2.79 7.52 2.67 20.09
Perseverative Thinking (WCST-64) 22.71 17.77 23.89 17.40 20.07
Immediate Verbal Recall (CVLT-II Trials 1–5 Total) 34.41 10.49 35.33 11.92 20.08
Neurophysiological Measures
Antisaccade Proportion Correct 0.54 0.25 0.50 0.28 0.15
Startle Reactivity (Block 1 pulse alone magnitude) 72.29 56.22 81.70 53.70 20.17
Startle Habituation 56.60 29.48 46.55 39.95 0.29
Prepulse Inhibition (30 msec) 34.69 26.34 29.28 23.70 0.22
Prepulse Inhibition (60 msec) 47.35 24.86 43.41 26.32 0.15
Prepulse Inhibition (120 msec) 62.57 25.12 58.23 27.49 0.17
P50 Amplitude (S1) 2.26 1.62 2.53 1.71 20.16
P50 Amplitude (S2) 1.27 1.13 1.23 1.06 0.04
S1–S2 Difference 1.00 1.25 1.30 1.34 20.23
P50 Suppression (%) 37.37 45.43 45.38 40.87 20.19
N100 Amplitude (S1) 22.53 2.23 22.74 2.41 0.09
N100 Amplitude (S2) 21.73 1.59 21.43 1.23 20.21
S1–S2 Difference 20.78 1.85 21.31 2.20 0.26
N100 Suppression (%) – – – – –
Mismatch Negativity (Fz) 21.42 0.97 21.26 1.34 20.14
P3a 1.77 1.50 1.85 1.50 20.05
Comparison of retested vs. not-retested subjects on baseline (Test Session 1) characteristics.
doi:10.1371/journal.pone.0039434.t001
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were 40-msec 115 dB[A] bursts of white noise. Prepulse stimuli
consisted of 20-msec noise bursts 15 dB above the 70 dB[A]
background, presented 30, 60 or 120 msec prior to the onset of the
startling stimulus. Our previous studies have demonstrated PPI in
the 60 msec condition to be optimal for detecting deficits in
schizophrenia patients [29,30,47,48]. Five pulse-alone trials were
presented at the beginning and end of the session to assess
habituation. In each of Blocks 2–3, there were 8 pulse-alone and 8
of each of the three prepulse trial-types presented in a pseudoran-
dom order with a 9–23 sec (15 sec average) intertrial interval.
P50 and N100 amplitudes and suppression. Subjects were
tested a reclining chair to minimize myogenic artifacts. EEG data
collection procedures, electrode locations, and data processing
steps were performed following our established methods
[24,28,29,31,32]. P50 and N100 processing was performed offline
at electrode Cz [12,49,50]. Auditory click pairs (1 msec duration,
93 dB, 500 msec inter-click interval, 10 sec inter-pair interval)
were presented to subjects. Testing was terminated after a mini-
mum of 120 click pairs free of gross muscle or eye blink artifacts
and were obtained using an automated threshold filter of +/2100
uVolts. Final data processing and EEG analyses were conducted
Table 2. One year stability of Clinical, Functional, Neurocognitive, and Neurophysiological Measures in Schizophrenia Patients and
Nonpsychiatric Comparison Subjects.
Schizophrenia Patients Nonpsychiatric Subjects
Main
Effects
Time 1 Time 2 Time 1 Time 2
Group
Time
Mean SD Mean SD Mean SD Mean SD
Clinical & Functional
SAPS Total 8.32 4.38 7.91 4.68
SANS Total 13.60 4.55 13.97 4.57
GAF-Modified 41.75 8.11 44.20 7.72
SOF Total 47.57 6.27 47.78 6.54
UPSA- Full 79.09 13.56 81.65 12.94
UPSA-Brief 74.21 18.03 76.24 16.11
Neurocognitive
WRAT-3 Reading 43.01 7.95 44.42 6.88 51.31 4.53 51.55 4.85 G
LNS-Forward 11.34 3.05 11.75 3.18 14.61 2.90 14.42 2.70 G
LNS-Reorder 7.27 2.79 7.61 2.66 10.86 2.68 11.12 2.63 G
WCST Persev Resp 22.71 17.77 21.93 17.11 10.46 9.32 9.15 9.22 G
CVLT-II List A 34.41 10.49 36.68 12.26 52.41 10.34 56.88 9.67 G,T
Antisaccade 0.54 0.25 0.57 0.27 0.76 0.24 0.80 0.22 G
Startle & PPI
Startle Magnitude 72.29 56.22 80.41 47.71 74.26 39.99 76.84 46.06
Habituation 56.60 29.48 46.19 37.39 54.63 27.96 62.74 22.05
PPI 30 34.69 26.34 31.78 22.85 38.81 21.70 38.98 21.15
PPI 60 47.35 24.86 45.14 25.99 52.42 34.14 58.48 22.98 G
PPI 120 62.57 25.12 62.62 27.59 65.87 21.82 66.67 25.38
P50 & N100
P50 S1 Amplitude 2.26 1.62 2.48 1.86 3.18 2.10 2.96 2.17
P50 S2 Amplitude 1.27 1.13 1.25 1.09 1.55 1.26 1.68 1.35
P50 S1–S2 1.00 1.25 1.23 1.31 1.63 1.61 1.29 1.47
P50% Suppression 37.37 45.43 39.94 48.15 45.00 46.81 35.72 46.26
N100 S1 Amplitude 22.53 2.23 22.48 2.38 24.16 3.24 23.43 3.08 G
N100 S2 Amplitude 21.73 1.59 21.35 1.34 22.18 1.81 21.99 1.69 G
N100 S1–S2 20.78 1.85 21.14 1.84 21.98 2.92 21.44 2.35
N100% Suppression – – 36.94 50.70 39.47 48.87 33.20 60.05
Mismatch Negativity & P3a
Mismatch Negativity 21.42 0.97 21.35 1.27 22.56 1.60 22.40 1.65 G
P3a 1.77 1.50 1.66 1.26 3.17 1.38 3.05 1.59 G
G: Significant group main effect.
T: Significant Time effect.
No Group by Time interactions were present.
doi:10.1371/journal.pone.0039434.t002
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offline and blind to group membership. Blink and baseline
corrections were performed, followed by a second and fully
automated artifact rejection screening for residual artifact exceed-
ing +/270 uVolts. Waveform averages were then generated and
filtered using 24 dB/octave rolloff, (FIR) filters at 10–50 Hz for
P50 and with a 30 Hz lowpass for N100 peak detections. P50 and
N100 amplitudes in response to the first (S1) and second (S2)
stimuli were selected automatically by a computer algorithm and
subsequently reviewed offline by a research technician blind to
subject diagnosis. For P50, the largest peak relative to a preceding
negative trough in the 40–80 msec range was selected for S1 and
S2 responses. S2 responses were further constrained to be within
10 msec of S1 responses [51]. N100 peaks relative to baseline were
selected in the 65–135 msec range [40]. Individual P50 and N100
amplitudes in response to each of the clicks as well as the S1–S2
amplitude differences and percent suppression (1-[S2/S1]*100)
were assessed.
Antisaccade (oculomotor inhibition). Oculomotor record-
ings were obtained in a quiet, darkened room with subjects seated
in front of a flat screen monitor with head stabilized using a chin
rest or bite bar. Horizontal eye movements were measured using
infra-red oculography (Eye Trak Model 310 eye movement
monitor, Applied Science Laboratories, Waltham, MA). Stimuli
consisted of square subtending about 0.35 degrees of visual angle.
A stimulus was presented at central fixation, per our established
methods [43,51]. Following a random 2.4 to 3.6 sec interval, the
fixation stimulus was turned off. Two hundred ms prior to fixation
extinction, peripheral cues were illuminated at 10 or 15 degrees of
visual angle to the right or left of center. After fixation extinction,
this stimulus remained present for another 800 ms. Finally
a 500 ms duration stimulus was presented indicating the location
of a correctly performed antisaccade. Subjects were instructed to
move their eyes as quickly and accurately as possible to the cue’s
mirror image (same amplitude, opposite direction). Prior to
commencing oculomotor testing, antisaccade cues were presented
and subjects were required to point to, in addition to looking at,
the proper location of gaze, insuring that all subjects understood
task instructions. Antisaccade cues were yellow, all other stimuli
were blue. Antisaccade data is analyzed with computerized pattern
recognition software. After artifactual responses are removed the
primary dependent measure is proportion of correct responses
divided by the total number of (artifact-free) responses.
Statistical Analyses
PASW Statistics version 18 was used for all statistical tests, with
significance defined as p,0.01. This a-level reflects that there are
5 classes of endophenotypes under investigation (neurocognitive,
antisaccade, startle/PPI, P50/N100, and MMN/P3a) and repre-
sents a reasonable balance of possible Type I and Type II errors
for the large sample of subjects. Differential attrition was assessed
by one-way Analyses of Variance (ANOVA) to determine if there
Figure 4. One year stability of candidate neurocognitive and neurophysiological endophenotypes. Intraclass correlation coefficients are
shown for schizophrenia patients (blue; n = 163) and nonpsychiatric comparison subjects (red, n = 58). The mean retest interval was 364.57 (SD: 23.83)
days.
doi:10.1371/journal.pone.0039434.g004
Characterization of Biomarkers of Schizophrenia
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e39434
were significant differences on baseline demographic, clinical,
cognitive, and functional characteristics between those subjects
who returned vs. failed to return for follow-up testing at one year.
Subsequent analyses focused on the participants that returned for
follow-up assessments. Effect-sizes (Cohen’s d) are presented for all
group comparisons. Repeated measures ANOVA were performed
with session and group, respectively, as within- and between-
subjects factors. This analytic strategy enables the evaluation of
whether: 1) schizophrenia patients differ from NCS on the key
measures (i.e., a group main effect; effect size calculations shown in
Figure 2); 2) the measures exhibit overall stability of means (i.e.,
a test session main effect; effect size calculations shown in Figure 3);
and 3) the patients and NCS differ in the amount of change across
the 1 year interval (group by test session interaction).
Stability was assessed via Type C intraclass correlation
coefficients (ICC) using a consistency definition from a two-way
mixed-effects model to provide an overall index of stability of T1
and second test (T2) measures in the patient and control groups
separately. The ICC is a conservative estimate of test–retest
reliability, because it is sensitive to group mean changes over time
in addition to intra-subject variability. The following descriptors of
reliability coefficients were used in accordance with established
guidelines [52]: ‘‘Low’’ 0–0.1; ‘‘Slight’’ 0.11–0.40; ‘‘Fair’’ 0.41–
0.60; ‘‘Moderate’’ 0.61–0.80; ‘‘Substantial’’ 0.81–1.0.
To determine whether changes in candidate endophenotypes
were independent of fluctuations in clinical symptoms, T1–T2
change (D) values for endophenotypes and positive and negative
symptoms over the retest interval were calculated. Pearson
correlations were assessed between D values in endophenotype
and SAPS and SANS.
Results
Evaluation of Differential Attrition
Since differential attrition can confound the interpretation of
results, demographic, clinical, cognitive, and functional character-
istics of schizophrenia patients at intake who returned (n= 163) vs.
failed to return (n= 178) for follow-up testing were examined
(a=0.01; 80% power to detect d = 0.35 effect) prior to conducting
primary analyses. Although this study aimed to retest only 100 SZ
and 50 NCS after 1 year, efforts were made to retest as many SZ
patients as possible. We anticipated that there may be some
important pre-existing differences in the baseline characteristics of
retested vs. non-retested patients that could account for the
attrition rate and potentially compromise the validity of the retest
results. Across 33 variables assessed (see Table 1), no significant
differences were observed between these two groups of patients in
demographic characteristics, global symptom ratings, functional
scales, cognitive, or neurophysiological variables. Although there
were no differences on global positive or negative symptom
summary ratings in the schizophrenia patients, inspection of the 9
individual SAPS and SANS symptom ratings revealed that
Figure 5. One year stability of clinical and functional measures in schizophrenia patients.
doi:10.1371/journal.pone.0039434.g005
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retested patients had slightly less severe ratings of delusions (means
(SD) retested = 3.05, SD=1.78; non-retested = 3.63 (1.51);
F = 10.68, df = 1,338, p,0.001; d= 0.35). The groups did not
differ in their level of independence in their community living
situation, the distribution of living environments (i.e., board and
care facilities, assisted independent living programs, independent
living), SOF scores, GAF ratings, UPSA total scores, neurocog-
nitive, or neurophysiological performances. Exploratory analyses
of baseline demographic, cognitive, and neurophysiological
variables in the NCS group revealed that the retested NCS were
slightly older than the non-retested subjects (means (SD)
retested = 45.97, SD=10.71; non-retested = 40.13 (11.53);
F = 11.4, df = 1,204, p,0.001; d= 0.50), but no other significant
differences were observed across 24 statistical comparisons in this
group. Thus, attrition does not appear to be substantially
associated with key dependent variables for either the schizophre-
nia patients or the NCS.
Group Differences and Evaluation of Potential Practice/
Interval Effects
Significant deficits were present in the schizophrenia patients
across all of the neurocognitive tests, antisaccade, PPI, N100
amplitudes, MMN, and P3a (Figure 2). Consistent with previous
findings, no significant group differences were present on startle
magnitude or habituation, and PPI in the 30 and 120 msec
conditions [29]. In contrast to our expectations, significant deficits
were not detected for any P50 measures, or N100 S1–S2
amplitude difference or suppression variables. Marginally signif-
icant test session effects were present on the CVLT-II test of
immediate verbal recall with both groups showing improvements
in their T2 assessments (Table 2, Figure 3). This improvement
roughly equated to recalling an additional 1–4 words (out of 80
possible) over the retest interval. While no significant group by test
session interactions were present across measures, only the CVLT-
II approached significance (F1,220 = 5.21, p = 0.023).
Figure 6. Summary of results: Longitudinal Endophenotype Ranking System LERS): Ranking biomarkers for use as
endophenotypes in genomic studies and as biomarkers in clinical research studies. Neurophysiologic and neurocognitive measures
are ranked based on the observed magnitude of deficits (1–4), test-retest reliability (1–5), and state independence (1–4) as shown in Figures 2, 3, 4, 5
and described in the results.
doi:10.1371/journal.pone.0039434.g006
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Evaluation of One-Year Test-Retest Stability
The majority of neurocognitive and neurophysiological mea-
sures demonstrated moderate to substantial one-year stability in
both NCS and schizophrenia patients (Figure 4) with average
ICCs across all measures exceeding 0.75. Indeed, 37 of 42
reliability assessments in the present study exceeded 0.60.
Consistent with previous studies, P50 and N100 ratio measures
did not show high stability. Similarly, percent startle habituation
was not stable in the schizophrenia patients. The clinical and
functional characteristics (Figure 5) of the schizophrenia patients
also demonstrated substantial stability over the one year retest
interval (mean ICCs= 0.83).
Assessment of State Independence of Endophenotypes
As shown in Table 2, the schizophrenia patients exhibited
significant clinical symptoms and functional impairments. Positive
and negative clinical symptoms and functional assessment ratings
were consistent across the 1 year retest interval. T1–T2 D scores in
clinical symptoms (SAPS D Mean: 0.43, SD: 3.58; SANS D
Mean=20.45, SD=3.53) and individual endophenotypes were
calculated in order to assess the extent to which variation in
clinical symptoms were associated with changes in endopheno-
types across the retest interval. Changes in P3a were modestly
associated with changes in positive (r = 0.21, p = 0.036) and
negative (r = 0.26, p= 0.007) symptoms. Changes in negative
symptoms were associated with changes in P50 S1 amplitude
(r = 0.19, p = 0.045) and P50 S1–S2 difference (r = 0.21, p = 0.03).
None of the remaining neurocognitive or neurophysiological
measures were significantly associated with changes in positive or
negative symptoms (all r,0.12, all p.0.10).
Discussion
The majority of neurophysiological and neurocognitive mea-
sures examined in this study fulfill the criteria as valid
endophenotypes for genomic studies and as robust biomarkers in
clinical studies. Specifically, these candidate endophenotypes are:
1) associated with illness as they exhibit significant deficits in
schizophrenia patients); 2) stable over 1 year in both patients and
controls; 3) relatively insensitive to modest fluctuations in clinical
symptoms; and 4) suitable for use as repeated measures since they
do not show practice effects. Figure 6 summarizes the cumulative
effect size ratings across of these 4 criteria, via a Longitudinal
Endophenotype Ranking System (LERS; cf. [53]). Related studies
have confirmed that many of these measures show significant
deficits in clinically unaffected relatives of schizophrenia patients,
are heritable and informative for the identification of genetic
variation in schizophrenia [3,7,22,54]. In addition, each measure
has independently been the focus of intense scientific inquiry that
has, in some cases, produced a rich literature describing
informative animal models with predictive and construct validity
[55] and detailed underlying neural and molecular substrates
[3,56].
Deficits in Patients
Mismatch negativity, P3a, PPI, oculomotor antisaccade, and
neurocognitive measures demonstrated significant deficits in
schizophrenia patients and stability over the retest interval. A
few of the neurophysiological measures are known to be sensitive
to antipsychotic medication effects, which may have contributed to
the results. Specifically, deficits in PPI and P50 suppression
measures are known to be opposed by second generation
antipsychotic medications [29,50,57–59]. Since this was a natural-
istic study designed to validate the use of these measures in even
larger-scale genomic studies where medications are virtually never
experimentally controlled, subjects were not stratified on the basis
of their medication type, gender, or smoking status–all factors
known to influence PPI, P50, and other measures [29,60–63]. It is
therefore possible that these or other confounding factors may
have contributed to the failure to detect significant and reliable
P50 and N100 amplitudes and gating deficits in the schizophrenia
patients. The modest reliability of ratio-based measures of P50 and
N100 gating is consistent with previous studies of normal subjects
over relatively brief retest intervals [64–68]. The results of this
study support examining constituent S1 and/or S2 component
amplitudes or non-ratio S1–S2 ERP amplitude difference
measures. The Consortium on the Genetics of Schizophrenia
(COGS) study which utilized a separate family-based sample of
subjects also found that P50 and N100 individual response
amplitudes and S1–S2 difference scores performed substantially
better than gating ratios in heritability [7,40] and genomic
analyses [3].
Stability Over 1-year
The stability of many of the neurophysiologic and neurocog-
nitive measures in schizophrenia patients was somewhat higher-
than-expected given the naturalistic study design that allowed for
changes in medications and clinical status over the 1 year follow-
up period. For example, 27% of patients underwent an addition,
subtraction, or substitution of their primary antipsychotic medi-
cation (without considering the many dosage or adjunctive
medication changes) over the test-retest interval. This robust
stability raises the question of whether participants in this study
were higher-functioning, asymptomatic, and therefore not repre-
sentative of a ‘‘real world’’ community sample. An answer to this
key question resides in the patient data: the retested vs. non-
retested patients did not differ substantially in baseline character-
istics. Many of the re-tested patients were neither high functioning
nor asymptomatic (see Table 1). For example, 41% of the retested
patients received maximal clinical severity ratings on hallucination
items from the SAPS, 70% received maximum anhedonia and
avolition ratings and, in terms of real-world function, 52% of
patients required assistance with basic financial management.
With respect to the stability of clinical assessment measures,
functional status and capacity are becoming more widespread in
schizophrenia research. Following the MATRICS initiative [69–
71], these types of assessments have been proposed as co-primary
endpoints in clinical trial studies of potential cognitive-enhancing
interventions. This study significantly advances the growing
literature on the psychometric properties of functional outcome
measures, including their long-term stability. For example, the
stability of the Scale of Functioning (SOF) has not been reported
previously. The substantial stability of the SOF (ICC=0.88)
supports its use in studies designed to characterize the global
psychosocial and community functioning (e.g., [24,28]. This scale
provides important information about community functioning
milestones such as occupational status, social relationships, and
level of independence in living situations that can be targeted by
novel pharmacologic and nonpharmacologic interventions [72–
74]. Likewise, the finding of high 1-year stability of the UPSA and
the abbreviated UPSA-Brief is consistent with and replicates
recent reports over both short [75] and longer [76] retest intervals.
It is possible that the assessment of patients across more
dynamic phases of illness, such as during the conversion from
prodromal states to first episode schizophrenia [77–80] or during
clinical exacerbations in already diagnosed schizophrenia patients
might yield stability coefficients that were lower than what was
observed in this more chronic outpatient cohort. Indeed, one
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could argue that the high stability observed in chronic patients is
attributable to the fact that many of the patients have reached the
nadir of their illness and are no longer experiencing dramatic
fluctuations in the underlying neural networks that contribute to
clinical symptoms and their related neurophysiological and
neurocognitive function. It therefore remains an open question
as to which if any of these measures will also serve as robust
vulnerability markers in high risk populations [80,81].
Independent of Fluctuations in Clinical Symptoms
Neurophysiological and neurocognitive measures were relative-
ly insensitive, accounting for ,5% of the variance, to modest
fluctuations in in clinical symptoms. The one exception was with
the P3a event-related potential where changes in both positive and
negative symptoms were correlated with changes in amplitude
over the test-retest interval, consistent with previous findings
[23,82]. The absence of associations with symptom changes does
not, however, invalidate the use of these measures as biomarkers of
clinical, cognitive, or functional response to therapeutic interven-
tions. Medications were not systematically controlled in this study,
and thus changes in clinical symptoms were not necessarily ones
that would optimally be ‘‘biomarker-sensitive’’ or indicative of
a therapeutic drug effect. Many of the characteristics of the present
measures such as deficits in patients, stability, utility as a repeated
measure, are also criteria for biomarkers of response to exper-
imentally controlled pharmacologic and non-pharmacologic inter-
ventions [16]. In fact, the Cognitive Neuroscience Treatment
Research to Improve Cognition in Schizophrenia (CNTRICS)
expert consensus panel has determined that only 2 neurophysio-
logical measures–MMN and PPI– are ‘‘already mature’’ and
among the most promising biomarkers for use in multi-site clinical
trials [83].
In conclusion, the cumulative pattern of results suggests that
these widely used neurophysiological and neurocognitive bio-
markers are robust, reliable, state-independent, and therefore valid
endophenotypes for ongoing genomic research studies where
endophenotypes are used to fill the ‘‘gene-to-phene’’ knowledge
gap. Genomic analyses from a subset of these participants have
been recently reported in this journal [3]. Family-based genetic
associations using these measures have also been reported for
a separate sample from the multi-site COGS study [2]. Future
studies are needed to assess the utility of these measures for
predicting conversion to psychosis, as biomarkers of response to
pharmacologic and nonpharmacologic [74,84] treatments, for
tracking disease progression across the course of illness [80], and
for the delineation of schizophrenia-related abnormalities across
genomic and neural networks [2,3].
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